Life Saving Drugs Program – Perinatal- or infantile-onset hypophosphatasia (HPP) – Guidelines

These guidelines contain the general, initial and ongoing eligibility requirements to access asfotase alfa (Strensiq®) for perinatal- and infantile-onset hypophosphatasia under the Life Saving Drugs Program.

Downloads

Life Saving Drugs Program – Perinatal- or infantile-onset hypophosphatasia (HPP) – Guidelines

We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.

Publication date:
Date last updated:
Publication type:
Guideline
Audience:
General public
Language:
English
Description:

These guidelines include:

  • General information about the Life Saving Drugs Program (LSDP)
  • Treatment of perinatal- and infantile-onset HPP through the LSDP
  • Drugs currently available for the treatment of perinatal- and infantile-onset HPP through the LSDP
  • Dosage
  • General, initial and ongoing eligibility requirements
  • LSDP funding conditions
  • Exclusion criteria.

Help us improve health.gov.au

If you would like a response please use the enquiries form instead.